Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on November 7, 2013, regarding events occurring on November 6, 2013. The filing serves to announce upcoming financial reporting for the three and nine months ended September 30, 2013, and the release of new clinical data.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of an upcoming earnings release rather than a financial statement itself.
Material Changes
No material financial changes are reported in this document as the actual financial results for the period ending September 30, 2013, have not yet been released.
Guidance, Outlook, and Management Commentary
- Earnings Release: The company expects to report financial results for the three and nine months ended September 30, 2013, after the market closes on November 12, 2013.
- Conference Call: A conference call and webcast will be held on November 12, 2013, to review financial results and provide updates on business matters.
- Clinical Data Update: New clinical data will be presented at the American Epilepsy Society Meeting in Washington, D.C., in December 2013.
- Specific Study: The first abstract, titled "Cognitive Effects of Extended-Release, Once-Daily Trokendi XR vs b.i.d. Immediate-Release Topiramate (TPM-IR, Topamax) in Healthy Volunteers," is scheduled for presentation on December 7, 2013.
Investor Verification Checklist
- Verify the actual financial results and conference call transcript released on November 12, 2013.
- Review the full clinical data abstracts presented at the American Epilepsy Society Meeting in December 2013.
- Confirm the impact of the Trokendi XR cognitive effects study on the company's product pipeline and regulatory strategy.